Safety of sublingual immunotherapy

Giorgio Ciprandi, G. L. Marseglia

Research output: Contribution to journalArticlepeer-review

Abstract

Sublingual immunotherapy (SLIT) is now recognized as a viable alternative to the classical injection route and it is currently used in everyday clinical practice in Europe. Sublingual administration is particularly attractive for children since it is completely pain-free. To date, no fatalities from SLIT have been reported, but two cases of anaphylaxis to inhalant allergens have been reported. The large majority of the adverse events reported in literature is described as mild. Most of them involve the mouth (burning or itching) or the gastrointestinal tract (stomach ache, nausea) and usually self-resolve in a few days without any intervention. At present, SLIT represents the main option for allergists, however, tablet immunotherapy could become an interesting alternative to sublingual drops.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalJournal of Biological Regulators and Homeostatic Agents
Volume25
Issue number1
Publication statusPublished - Jan 2011

Keywords

  • Children
  • Safety
  • Sublingual immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research

Fingerprint Dive into the research topics of 'Safety of sublingual immunotherapy'. Together they form a unique fingerprint.

Cite this